+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Prostate Cancer Nuclear Medicine Diagnostics Market Research Report by Type (PET and SPECT), Product, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 227 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5639599
UP TO OFF until Mar 31st 2023
The Global Prostate Cancer Nuclear Medicine Diagnostics Market size was estimated at USD 920.51 million in 2022, USD 1,032.95 million in 2023, and is projected to grow at a CAGR of 12.69% to reach USD 2,394.73 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Prostate Cancer Nuclear Medicine Diagnostics Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Prostate Cancer Nuclear Medicine Diagnostics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Prostate Cancer Nuclear Medicine Diagnostics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Prostate Cancer Nuclear Medicine Diagnostics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Prostate Cancer Nuclear Medicine Diagnostics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market is studied across PET and SPECT.
  • Based on Product, the market is studied across C-11, F-18, and Ga 68 PSMA.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Prostate Cancer Nuclear Medicine Diagnostics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Prostate Cancer Nuclear Medicine Diagnostics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Prostate Cancer Nuclear Medicine Diagnostics Market, including Bayer AG, Blue Earth Diagnostics, Inc., Bracco Diagnostic Inc., Cardinal Health, Inc, General Electric Company, Global Medical Solutions LLC, Jubilant DraxImage, Inc., Jubilant Pharma Limited, Lantheus Holdings, Inc., NCM-USA LLC, NorthStar Medical Radioisotopes, LLC, Novartis AG, Petnet Solutions Inc. by Siemens Healthcare Private Limited, SHINE Medical Technologies, LLC, and Telix Pharmaceuticals Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Prostate Cancer Nuclear Medicine Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Prostate Cancer Nuclear Medicine Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Prostate Cancer Nuclear Medicine Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Prostate Cancer Nuclear Medicine Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Prostate Cancer Nuclear Medicine Diagnostics Market?
6. What is the market share of the leading vendors in the Global Prostate Cancer Nuclear Medicine Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Prostate Cancer Nuclear Medicine Diagnostics Market?
Frequently Asked Questions about the Global Prostate Cancer Nuclear Medicine Diagnostics Market

What is the estimated value of the Global Prostate Cancer Nuclear Medicine Diagnostics Market?

The Global Prostate Cancer Nuclear Medicine Diagnostics Market was estimated to be valued at $920.51 Million in 2022.

What is the growth rate of the Global Prostate Cancer Nuclear Medicine Diagnostics Market?

The growth rate of the Global Prostate Cancer Nuclear Medicine Diagnostics Market is 12.6%, with an estimated value of $2394.73 Million by 2030.

What is the forecasted size of the Global Prostate Cancer Nuclear Medicine Diagnostics Market?

The Global Prostate Cancer Nuclear Medicine Diagnostics Market is estimated to be worth $2394.73 Million by 2030.

Who are the key companies in the Global Prostate Cancer Nuclear Medicine Diagnostics Market?

Key companies in the Global Prostate Cancer Nuclear Medicine Diagnostics Market include Bayer AG, Blue Earth Diagnostics, Inc., Bracco Diagnostic Inc., Cardinal Health, Inc, General Electric Company, Global Medical Solutions LLC, Jubilant DraxImage, Inc., Jubilant Pharma Limited and NCM.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of prostate cancer worldwide necessitates early diagnosis
5.1.1.2. Potential development of novel imaging agents to enhance prostate cancer detection
5.1.1.3. Increasing adoption of diagnostic procedures such as PET diagnostic tool attributed to higher accuracy
5.1.2. Restraints
5.1.2.1. Relatively high cost of the testing
5.1.3. Opportunities
5.1.3.1. Availability of reimbursement policies in developed and developing economies
5.1.3.2. Rising research for the development of innovative imaging agents
5.1.4. Challenges
5.1.4.1. Stringent regulations pertinent to storage and use of radiopharmaceuticals
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Prostate Cancer Nuclear Medicine Diagnostics Market, by Type
6.1. Introduction
6.2. PET
6.3. SPECT

7. Prostate Cancer Nuclear Medicine Diagnostics Market, by Product
7.1. Introduction
7.2. C-11
7.3. F-18
7.4. Ga 68 PSMA

8. Americas Prostate Cancer Nuclear Medicine Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Product Portfolio Analysis, By Key Player
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Bayer AG
12.2. Blue Earth Diagnostics, Inc.
12.3. Bracco Diagnostic Inc.
12.4. Cardinal Health, Inc
12.5. General Electric Company
12.6. Global Medical Solutions LLC
12.7. Jubilant DraxImage, Inc.
12.8. Jubilant Pharma Limited
12.9. Lantheus Holdings, Inc.
12.10. NCM-USA LLC
12.11. NorthStar Medical Radioisotopes, LLC
12.12. Novartis AG
12.13. Petnet Solutions Inc. by Siemens Healthcare Private Limited
12.14. SHINE Medical Technologies, LLC
12.15. Telix Pharmaceuticals Limited

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET DYNAMICS
FIGURE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2030
FIGURE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2030
FIGURE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY C-11, 2018-2030 (USD MILLION)
FIGURE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY F-18, 2018-2030 (USD MILLION)
FIGURE 22. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GA 68 PSMA, 2018-2030 (USD MILLION)
FIGURE 23. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 24. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 25. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 26. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 27. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 28. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 29. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 30. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 31. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 32. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 33. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 34. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 35. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 37. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 38. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 39. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. MALAYSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. PHILIPPINES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 46. SINGAPORE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. TAIWAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. THAILAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. VIETNAM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 55. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 77. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 78. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY C-11, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY C-11, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY C-11, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY F-18, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY F-18, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY F-18, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GA 68 PSMA, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GA 68 PSMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GA 68 PSMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 33. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 34. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 36. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 37. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 48. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 51. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 53. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 54. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 57. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 60. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 63. MALAYSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. MALAYSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. PHILIPPINES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. PHILIPPINES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. SINGAPORE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. SINGAPORE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 72. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. TAIWAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. TAIWAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 77. THAILAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 78. THAILAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. THAILAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 81. VIETNAM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. VIETNAM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 87. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 88. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 91. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 93. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 94. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 97. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 99. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 100. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 103. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 105. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 106. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 109. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 114. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 115. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 117. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 120. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 121. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 136. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 139. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 142. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 150. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 151. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 152. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 153. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 154. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 155. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 156. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET MERGER & ACQUISITION
TABLE 157. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 158. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 159. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET INVESTMENT & FUNDING
TABLE 160. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 161. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

  • Bayer AG
  • Blue Earth Diagnostics, Inc.
  • Bracco Diagnostic Inc.
  • Cardinal Health, Inc
  • General Electric Company
  • Global Medical Solutions LLC
  • Jubilant DraxImage, Inc.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • NCM-USA LLC
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • Petnet Solutions Inc. by Siemens Healthcare Private Limited
  • SHINE Medical Technologies, LLC
  • Telix Pharmaceuticals Limited

Methodology

Loading
LOADING...